The business of making vaccines

Cormac Sheridan

With a growing need for better and more plentiful vaccines, traditional vaccine companies are responding by increasing manufacturing capacity, the biotech industry, with innovative products. Both are surely needed.

The landscape in vaccine manufacturing has changed radically over the past 30 years. In 1967, over a dozen licensed vaccine manufacturers operated in the United States alone. This number has since collapsed through mergers and exits to barely a handful. Low profit margins, the introduction in 1980 of good manufacturing practices (GMP) to vaccine production (which caused manufacturing costs to skyrocket) and the specter of liability all contributed to the contraction in the industry. Five companies—Chiron (Emeryville, CA, USA), GlaxoSmithKline (Brentford, UK), Merck (Whitehouse Station, NJ, USA), Sanofi Pasteur (Lyon, France) and Wyeth (Madison, NJ, USA)—account for close to 90% of the influenza vaccine supply in the world (Fig. 1). Now the landscape may be about to change again, as attention is riveted on vaccine supplies, in anticipation of a possible influenza pandemic.

Bouncing back

The price for a vaccine has jumped from a few dollars for a course of routine pediatric vaccines in the 1980s to over $200 for Wyeth’s blockbuster vaccine Prevnar (pneumococcal 7-valent conjugate vaccine) against meningitis and bloodstream infections. Some say Prevnar has transformed the vaccine business almost overnight. Although vaccine sales on the whole have risen rather modestly over the past 20 years, from $2 billion in 1982 to only over $8 billion today—a pittance compared with the drug market as a whole—recent projections show the vaccine market growing at double digits annually, which outpaces other infectious disease sectors. The new crop of vaccines, like Merck’s Gardasil (a recombinant vaccine comprising human papilloma virus, HPV) subtypes 6, 11, 16 and 18), which was recently shown to be 100% effective in preventing cervical cancer, is projected to bring in $750 million to over $1 billion annually.

Keeping up with the demand for new vaccines, let alone responding to possible epidemics, natural or man-made, could well overwhelm the already stretched-to-capacity manufacturers of these prophylactics. Although vaccine manufacturers are loath to discuss capacity right now in the highly politicized environment created by the fear of an influenza pandemic, a look at their activity suggests that they are concerned about capacity and committed to increasing it. Each of the top five vaccine-producing companies has increased capacity either through acquisitions or through building facilities from scratch (Table 1).

The flurry of big pharma merger and acquisition activity this fall, which centered on targets with large influenza vaccine franchises, underlines the extent to which vaccines are now considered a worthwhile investment opportunity by the industry’s biggest guns. GlaxoSmithKline’s $1.4 billion bid for ID Biomedical, of Vancouver, Canada, and Basel-based Novartis’s attempt to become the outright owner of Chiron are evidence of an ongoing revival of this previously viewed low-profit, Cinderella sector.

Under the regulatory microscope

Several factors have kept new companies from entering the fray, and might continue to do so going forward, even with the optimistic market projections. The high level of capital expenditure involved in vaccine production, combined with its complexity (Table 2) have enabled the larger players to maintain their dominance. Many vaccines are low-margin products, so large economies of scale, combined with deep production experience have proved effective barriers to entry. “Every single step in the manufacture of a vaccine is extremely challenging,” says Philippe Monteyne, vice president of worldwide cervical cancer vaccine Cervarix operations with GSK Biologicals. However, although many production methods, such as egg-based production of influenza vaccines, are decades old, they are constantly being refined to keep pace with developing regulatory requirements. “We can’t say we are making vaccines like we were doing even five or ten years ago,” he says.

The US Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research (CBER), which regulates the production of vaccines, is steering all companies falling within its remit toward a modern systems-based approach to quality management. Its officials have been critical of vaccine producers, in particular, for failing to put sufficient controls in place throughout the manufacturing process to allow for full investigation of product failures. According to Gordon Richman, vice president and general counsel at EduQuest, (Hyattstown, MD, USA), a consultancy that advises on...
Opportunity knocks

Although the five big players dominate the industry at present, their hegemony is being challenged from below by innovative biotech companies working on creating new and more robust delivery systems (Box 1) and, as demonstrated by the recent Novartis bid, from within their own peer group also.

This dynamic is easily explained. The vaccines market enjoyed a compound annual growth rate of over 25% between 1999 and 2003, according to John Savopoulos, head of the infectious disease team at London-based market analysts Datamonitor. Estimated global revenues rose from $3.5 million to $8.8 billion during this time, and double-digit sales growth is set to continue for the foreseeable future. “That’s why the market is attractive, as there are not many areas in healthcare that offer that kind of growth,” he claims. Precise forecasting is difficult, he says, as a substantial level of vaccine purchasing is driven by public policy recommendations, whose implementation is not always predictable. Nevertheless, several drivers are propelling the market. Demand for influenza vaccination, which must be redesigned each year to match the current strain, continues to rise. In the United States, the Atlanta-based Centers for Disease Control and Prevention’s (CDC) Healthy People 2010 initiative, which aims to boost infectious disease immunization

### Table 1 Vaccine franchises and increases to manufacturing capacity by the top five vaccine producers

| Company        | Major vaccine programs                                             | Development pipeline                                                                 | Increases to manufacturing                                      |
|----------------|--------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Chiron         | Flu, meningococcal meningitis, *Haemophilus influenzae* type 1b meningitis, diptheria, measles, mumps, whooping cough, pneumococcal disease, polio, rubella, tetanus, rabies, yellow fever, chola, tick-borne encephalitis | Meningococcal disease (conjugate), hepatitis C virus (subunit), HIV (subunit), flu (made in cell culture), meningitis (membrane protein subunit) | Acquired Italy-based Scalvo (1992)                                |
|                |                                                                    |                                                                                      | Acquired Germany-based Behring (1998)                             |
|                |                                                                    |                                                                                      | Acquired UK-based PowerJect (2003) $97 million to remediate Liverpool plant |
| GlaxoSmithKline| Diphtheria, tetanus, whooping cough, hepatitis A and B, flu, polio (Sabin), measles, mumps, rubella, meningococcal meningitis, smallpox, rotavirus (approved outside the US) | HPV (virus-like particle in baculovirus), rotavirus (live human, attenuated, for US), pneumococcal (conjugate), flu (made in cell culture), meningitis (conjugate, trivalent), Dengue fever (attenuated), herpes (subunit), HIV (subunit) hepatitis E (virus-like particle) | Acquired ID Biomedical Corp. in 2005 for egg-based influenza vaccine                                      |
|                |                                                                    |                                                                                      | Acquired Marietta vaccine site in PA from Wyeth for cell culture-based influenza vaccine for $100 million |
|                |                                                                    |                                                                                      | Acquired Hungary vaccine company in 2002                          |
|                |                                                                    |                                                                                      | Announced plans to double capacity of Dresden Plant, 2005        |
|                |                                                                    |                                                                                      | Broke ground for a new manufacturing facility in Durham, North Carolina, 2004 |
| Merck          | *Haemophilus influenzae* type b, hepatitis A, hepatitis B, measles, mumps, rubella, pneumococcal disease, chicken pox | HPV (virus-like particle in yeast), rotavirus (live human/bovine attenuated), shingles (live attenuated), flu (live, attenuated, nasal), tuberculosi (subunit), HIV (live recombinant) |                                                                 |
| Sanofi-Pasteur | Whooping cough, diptheria, *Haemophilus influenzae* type 1b, meningococcal meningitis, tetanus, tuberculosi, typhoid fever, chola, yellow fever, mumps, polio, measles, rubella, flu, hepatitis A and B, rabies, chicken pox, Japanese encephalitis | AIDS (canarypox, subunit vaccine, and live recombinant), Dengue (live attenuated, trivalent), flu (inactivated), typhoid (conjugate), respiratory syncytial virus (RSV, live, attenuated), pneumococcal disease (conjugated 11-valent), meningitis (conjugate, trivalent) | Broke ground on a new manufacturing facility 2005 |
|                |                                                                    |                                                                                      | Received a $95-million grant from US Department of Health and Human Services |
|                |                                                                    |                                                                                      | Department of Health and Human Services to develop cell culture technology, refit development facility and prepare plans for a manufacturing facility in the US |
|                |                                                                    |                                                                                      | Invested $200 million in PA facility                               |
| Wyeth          | *Haemophilus influenzae* type b, pneumococcal disease, triangle cattle vaccines, feline vaccines (combination), canine parvovirus/dis-temper, chicken bursal disease, horse flu, dog giardia, dog Lyme disease, cattle pneumonia, swine mycoplasma, meningococcal meningitis type C | HIV, RSV (subunit and live attenuated nasal), pneumococcal (conjugate, 9-valent), HIV (DNA vaccine), meningococcal meningitis type B | Built a new plant in Ireland                                      |

Source: Company websites and World Health Organization (WHO), http://www.who.int/vaccine_research/documents/en/Status_Table_April05.pdf
rates among high-risk groups, is another important driver. Savopoulos also expects the most developed Asian states to begin harmonizing their immunization policies with those of the United States, particularly in the wake of the 2003 severe acute respiratory syndrome (SARS) epidemic.

The vaccine industry’s big players are less open to innovation at present, Savopoulos says, as the sector went through a phase of exploration with “weird and wonderful” technologies, such as therapeutic vaccines (sometimes referred to as pharmacines), but with little success. Prevnar demonstrated the commercial feasibility of developing a product with less technical risk. “The big guys seem to be quite happy with what they’re doing these days,” says Savopoulos.

Even cell culture, which has been proposed as one potential improvement on influenza vaccines production, may not make much of an impact, he argues, as it will still be limited by the same ‘dirty’ purification processes currently used with egg-based vaccines. Thus far, moreover, recombinant vaccines produced in cells do not appear to be as immunogenic as their egg-based counterparts. “From our research, it’s not all it’s cracked up to be,” he says. He estimates that cell culture-based influenza viruses may take just 15% of the overall market by 2010.

The historic underinvestment in vaccine innovation, combined with the focus of the ‘big five’ players on large-scale product franchises, has provided biotech companies with a plethora of niche opportunities (Tables 3, 4 and 5). According to Alexander von Galbain, CEO of Vienna-based Intercell, the replacement of currently approved vaccines produced using ‘obscure’ material represents one obvious opportunity. Intercell recently moved its lead product, a vaccine for Japanese encephalitis virus (JEV) infection into pivotal trials. Intercell’s candidate product is based on an inactivated virus grown in tissue culture. In contrast, the vaccine currently on the market is extracted from the brains of suckling mice, and, he says, causes a high level of allergic reactions, as well as other side effects. Acambis (Cambridge, MA, USA), is targeting JEV as well, with a live attenuated recombinant vaccine based on a chimeric yellow fever viral vector. It has received FDA approval to initiate a pivotal trial, says CSO Thomas Monath.

Biotech companies with maturing pipelines of vaccine products inevitably face decisions on manufacturing—whether to partner with existing manufacturers, to outsource while retaining product exclusivity (via a contract manufacturing organization (CMO)) or whether to develop an in-house manufacturing capability. However, outsourcing might not be the answer, according to Peter Wulff, CEO of Bavarian Nordic (Kvistgaard, Denmark). “Many CMOs either ask for cash upfront to pay for the investment needed to do the production or they depreciate the cost over the first few production runs so the biotech company has to carry a lot of cost upfront either way,” he says. Intercell acquired a 30,000-square-foot facility in Livingston, Scotland, in 2004. Bavarian Nordic, which is vying with Acambis to win a large US government contract for a stockpile of smallpox vaccine, based on the modified vaccinia Ankara vector, also acquired a production facility, in Kvistgaard, Denmark, from Orion Pharma (Espoo, Finland).

The US Project BioShield program has been a significant source of recent growth, with US authorities spending hundreds of millions of dollars on stockpiles to protect against anthrax and smallpox (Table 6), as well as smaller investments for new product development (Table 7). These agents were until very recently off-radar for biotech companies, but they now represent important sources

| Table 2 Manufacturing processes for vaccines |
|------------------------------------------------|
| Vaccine type | Process | Examples |
|---------------|----------|----------|
| Attenuated microbial cells | Growth and purification of microbial cells adapted or engineered to delete pathogenicity, retaining immunogenicity | Mycobacterium tuberculosis vaccine (TICE BCG, Organon Teknika; MycoBax, Aventis Pasteur) Salmonella typhi vaccine (Vivotif, Berne) |
| Live microbial vector | Growth and purification of nonpathogenic microbial cells carrying added gene for an immunogenic protein | Vaccinia and Salmonella typhi being developed to carry multiple antigens; in clinical trials |
| DNA vaccine | Extraction and purification of plasmid DNA from bacterial cells containing desired gene in the plasmid | West Nile virus for horses vaccine (West Nile Innovator, Wyeth) Salmon infectious hematopoietic necrosis virus vaccine (Apex-IHN, Aqua Health/Novartis) |
| Recombinant, purified protein, excreted or cell-associated | Growth of recombinant bacteria, yeast or cell culture where recombinant protein, cell lysis (for cell-associated proteins), isolation and purification of the protein | Bordetella pertussis vaccine (Tripedia, Aventis Pasteur) Hepatitis B (Recombivax, Merck) |
| Conjugated polysaccharides | Growth of bacterial culture, extraction and purification of capsular polysaccharides, preparation of carrier protein, conjugation to carrier protein | Haemophilus influenzae b vaccine (HibTiter, Wyeth) Streptococcus pneumoniae vaccine (Prevnar, Wyeth) Neisseria meningitidis vaccine (Menjugate, Chiron/ Merck; Neysvac, Baxter/Shire) |
| Live attenuated viruses | Growth of cells (from cell banks of continuous cells or isolation of primary cells), infection with attenuated virus, isolation and purification of virus | Measles, mumps, rubella vaccine (M-M-R II, Merck) Varicella vaccine (Varivax, Merck) Yellow fever vaccine (YF-Vax, Aventis Pasteur) |
| Multiple antigen peptide vaccines | Linking of synthetic peptide antigens to a synthetic backbone (e.g., polylysine) | Tuberculosis in clinical trials |
| Virus-like particles | Growth of cells, infection by virus or recombinant virus producing nonreplicating, noninfectious, particles with intact immunogenic antigens, isolation and purification of the virus-like particles | HPV, late-stage clinical trial (Gardasel, Merck) |
| Live viral vectors | Growth of cells, infection with genetically engineered replicating nonpathogenic viruses containing added gene of interest, isolation and purification of virus | HIV-canary virus (clinical trials) |

Source: WHO, http://www.who.int/vaccines-access/quality/contractmanufdb/vaccinetypes_processes.htm and Immunization Action Coalition (St. Paul, MN, USA)
Injectible DNA-based vaccines received a double boost this year when vaccines against infectious hematopoietic necrosis virus (IHNV) in farmed salmon and against West Nile virus in horses gained approval in Canada and the United States, respectively. Proof-of-concept was first demonstrated in mice more than a decade ago, but that initial promise did not meet expectations. Similar effects were not seen in human trials, although according to Vijay Samant, CEO of San Diego, California-based DNA vaccine specialist Vical, too much was expected of the technology too quickly. “People ran with this very exciting technology and applied it to very tough targets,” he says. Moreover, Merck, a Vical partner, was the only firm to actually subject the technology to an efficacy trial. “Since then, nobody has done a double-blinded infectious disease efficacy trial,” he says.

DNA vaccines, based on bacterial plasmids, are an attractive option, because they are precisely defined, can be easily cultivated in recombinant bacteria and appear to be safe. They also contain the CpG motifs characteristic of bacterial DNA, which trigger innate immune responses. Aqua Health of Charlottetown, Prince Edward Island, Canada, the company that gained approval for the salmon vaccine, is a Vical licensee. So too is Harlow, UK-based Merial, an animal health joint venture between Sanofi-Aventis and Merck, which aims to gain approval for a canine melanoma vaccine next year. “We [will then] have three weight categories (small, medium and large animals) in which we have validated this technology,” Samant says.

Delivery of sufficient quantities of DNA to elicit a strong immune response has been the biggest obstacle to progress. Several avenues are being explored. Vical uses adjuvants based on cationic lipids to provide a degree of physical protection to the DNA before it encounters a cell membrane. But more high-tech methods are also being developed. PowderMed was spun out of Chiron last year to continue development of a needle-free DNA vaccine delivery method the latter gained when it purchased Oxford, UK-based firm Powderject in 2002. A version of the technology, now called particle-mediated epidermal delivery, has been around for over a decade. It relies on the use of tiny gold particles as carriers of plasmid DNA. These are propelled at near-supersonic speed by pressurized helium gas to penetrate antigen-presenting dendritic cells and keratinocytes beneath the surface of skin. Once inside a cell, the plasmid DNA elutes off from the particle and becomes transcriptionally active. CEO Clive Dix, who had joined Powderject from GlaxoSmithKline in 2001, says the technology can overcome the delivery problems that have hampered progress with DNA vaccines in humans as it requires only one or two micrograms of DNA to elicit a response. “The people that talk to us [are] slightly skeptical still, I have to say,” Dix says. But the approach could offer a rapid and novel approach to manufacturing. “We can build a factory that would have the capacity to produce 150 million doses of this vaccine in three months, from the date when somebody says: ‘this is the vaccine to produce’.” PowderMed plans to move its lead project, a vaccine for pandemic influenza, into human trials next year.

Intramuscular electroporation is also gaining some ground, after the acquisition earlier this year of a Norwegian pioneer in the area, Inovio, by Genetronics Biomedical. The merged entity, Inovio Biomedical, of San Diego, is focusing on oncology but has licensed DNA vaccine applications to partners, including Chiron and Vical. Chiron’s Jeffrey Ulmer says it can increase the efficiency with which DNA is taken up by target cells by 100-fold, although the technology still has to prove itself in terms of safety, tolerability and practicability. PowderMed’s technology can now be manufactured as a disposable device. “One would imagine, with technological developments, one could apply the same principle to electroporation, says Ulmer.”
Table 3  Selected biotech companies dedicated to the research, development and manufacture of prophylactic vaccines

| Company (location) | Vaccine focus (development phase, if any) | Technology | Business strategy |
|--------------------|------------------------------------------|------------|------------------|
| Acambis (Cambridge, UK and Cambridge, MA, USA) | Typhoid (marketed) and smallpox (marketed), yellow fever, Japanese encephalitis, West Nile, Dengue, *Clostridium difficile* | Vaccinia vaccines, live viral vectors attenuated by recombinant technology and vaccines using inactivated bacterial toxins | Development and manufacture of vaccines. Partnered with Baxter Healthcare for distribution |
| Alphavax (Research Triangle Park, NC, USA) | HIV (phase 1), cytomegalovirus, influenza, SARS and three biodefense targets, Marburg virus, viral encephalitis and botulinum toxins | Live viral vectors based on alphavirus replicon expressing viral or bacterial antigens | Development of vaccine delivery systems. Some company funded, others grant funded, others partner funded. Partnered with Wyeth for herpes simplex virus, HPV, flu and respiratory syncytial virus |
| Bavarian Nordic | Smallpox, HV, Japanese encephalitis, Dengue and measles | Live viral modified vaccinia Ankara (MVA) vectors | Development and manufacture vaccines. Partnered with GSK for smallpox, IDM Pharma for HIV vaccines, Impfstoffwerk Dessau-Tornau GmbH for manufacturing |
| Berna Biotech | Marketed: influenza, typhoid, hepatitis A and hepatitis B. Under development: hepatitis B (phase 3), yellow fever (phase 3), *Pseudomonas aeruginosa* (phase 3) | Virosome-based technology (liposomes containing viral capsid components) for antigen presentation, live virus/ bacteria attenuated by recombinant technology as well as a recombinant subunit vaccine | Development and manufacture of vaccines. Partnered with Corixa, Orphan Europe, Chiron and Solvay |
| Bioport (Lansing, MI, USA), a subsidiary of Emergent BioSolutions (Gaithersburg, MD, USA) | Anthrax | Aluminum hydroxide–adsorbed cell-free vaccine prepared from *Bacillus anthracis* strain V770-NP1-R | Manufacture and supply US government stockpile of only FDA-approved anthrax vaccine |
| Cambridge Biostability (Cambridge, UK) | Enterotoxic *Escherichia coli* | Technology for stabilizing vaccines in sugar glass and suspension in fluorocarbon liquids | Vaccine formulation and delivery. Partnered with Acambis |
| CSL (Parkville, Australia) | Diphtheria with tetanus vaccine, (marketed), Q Vac (Coxiella burnetii vaccine, marketed) Tet-Tox (Tetanus vaccine, marketed) Fluvar (influenza vaccine, egg-based, trivalent, marketed) Plagues vaccine (Yersinia pestis marketed); HPV (Phase 3, licensed to Merck) HCV (Phase 2, licensed to Chiron) | Iscomatrix adjuvant, Virus-like particles | Licensed vaccines to Merck & Chiron, distribution partner for Merck & Chiron |
| DynPort Vaccine Company (Frederick, MD, USA) | Botulism, plague, tularemia and Venezuelan equine encephalitis | Live-attenuated vaccines, recombinant subunit vaccines and vaccine delivery systems | Subcontracts vaccine programs to research centers and companies. Partnered with Avant and Baxter and The National Institute of Allergy and Infectious Diseases |
| ID Biomedical (Vancouver, BC) | Influenza, *Neisseria meningitides*, pneumococcal disease and group A streptococcus infections | Combination nasal delivery system and adjuvant made from nanospheres of bacterial proteins; recombinant subunit vaccines | Development of vaccines Acquired by GSK |
| Intercell (Vienna) | Japanese encephalitis virus (phase 3) and hepatitis C (phase 2), streptococcal hospital-acquired infections and tuberculosis | Recombinant protein vaccines and synthetic adjuvant combining an antimicrobial peptide, and an immunostimulant oligodeoxynucleotide | Vaccines and other immunotherapies as well as antigen/epitope identification/validation services. Partnered with Merck |
| Iomai (Gaithersburg, Maryland, USA) | Transcutaneous vaccination two influenza vaccines (phases 1 and 2), traveler’s diarrhea (phase 2) and anthrax (phase 1) | Needle-free, transcutaneous vaccination using cholera toxin or heat-labile enterotoxin as adjuvants. | Development of vaccines |
| Noblion (Boxmeer, The Netherlands) part of the Akzo Nobel Pharma Group | Influenza, traveler’s diarrhea, sexually transmitted diseases | Biofermentation expertise | Contract manufacture of vaccines. Works with other Akzo companies: Intervet (animal vaccines), Organon (human pharmaceutical production). Partnered with BioDiem for flu vaccine |
| VacGen (Brisbane, CA, USA) | Anthrax, smallpox and bacterial meningitis | Recombinant subunit vaccines with alum-adjuvant as well as vaccinia vaccine | Development and manufacture of biodefense vaccines with facilities in California and South Korea. Partnered with Celltrion Incheon (South Korea) to build production facilities |

billion in 2004, despite production problems, and it racked up a further $714 million during the first half of 2005. Efficient prelaunch marketing activity, which included gaining the backing of the key influencers in the area, enabled the company to set a relatively high price for the product, thus ensuring its commercial success, says Savopoulos, “it basically comes down to effective prioritization of your research programs and putting your money behind the right horse.” GlaxoSmithKline and Merck both want to follow suit. Each is developing an HPV vaccine, based on L1 virus-like particles, to protect against cervical cancer. Merck’s biologic license
application filing for its product, Gardasil, which protects against two HPV strains implicated in cervical cancer and two more implicated in the development of genital warts, is imminent. Sanofi Pasteur MSD, its European joint venture with Sanofi Pasteur, is due to file an imminent application filing for its product, Gardasil, which developed its rival product, Cervarix, in collaboration with MedImmune (Gaithersburg, MD, USA), aims to file in Europe in 2006 but has yet to disclose the time frame for a US filing. Although Merck may be first to market with its product, which it codeveloped with CSL (Parkeville, Australia), GlaxoSmithKline stands to gain a royalty stream from this franchise as well, following the settlement of a patent dispute between the two companies earlier this year. Vaccines now represent an important element of GlaxoSmithKline’s growth strategy, and were, uncharacteristically, the main focus of a pipeline update during the summer.

### Table 4 Selected public biotech companies with a business interest in prophylactic vaccine development

| Company (location) | Prophylactic vaccine focus (development phase, if any) | Technology | Business strategy |
|--------------------|--------------------------------------------------------|------------|------------------|
| Avant Immunotherapies (Needham, MA, USA) | Rotavirus (marketed by GSK), HIV (phase 1), anthrax (phase 1), Salmonella vaccine for chickens (marketed) and plague | Attenuated viral and bacterial vaccines and use of anthrax toxin fusion to target antigens for major histocompatibility complex class I processing | Vaccines and other immunotherapeutics. Partnered with Pfizer (food safety), GlaxoSmithKline (rotavirus), the International Vaccine Institute, Dynport and Lohmann Animal Health International. Opening manufacturing facility in Fall River, Massachusetts |
| Antigen Express (Worcester, MA, USA), a wholly owned subsidiary of Genevec Biotechnology (Toronto) | H5N1 influenza and SARS | li-key protein fusions to viral or bacterial epitopes to facilitate MHC class II presentation. li suppression platform to augment DNA vaccines | Developing a broad range of vaccines and therapeutics based on li family of MHC-regulating proteins. Partnering with Chinese Academy of Sciences (SARS) |
| Crucell (Leiden, The Netherlands) | Ebola, influenza, malaria, and West Nile virus | Inactivated split and whole viral vaccines. Replication-deficient adenovirus vectors expressing microbial antigens. | Vaccines and antibody products. Partnered with Chiron, MedImmune, Merck, Sanofi Pasteur and Vaxin |
| Dong Shin Pharma (Seoul, Korea) | Influenza, Japanese encephalitis, rubella | Inactivated whole virus or inactivated viral subunit vaccines | Vaccines, biopharmaceuticals and nutritional products |
| Epimmune (San Diego, CA, USA) | HIV (phase 1/2) | Computer algorithms for epitope identification and selection together with proprietary adjuvant peptide sequence (PADRE) | Therapeutic vaccines in infectious disease and cancer. Partnered with Innogenetics |
| Henderson Morley (Birmingham, UK) | Genital herpes | ‘Intracellular’ vaccines based on extracts of infected cells from which herpes simplex virus type 2 DNA and particles have been removed. Previral DNA replication enveloped virus vaccines | Anti-viral treatments and diagnostics and herpes simplex type 2 vaccines |
| Innogenetics (Ghent, Belgium) | Hepatitis C (phase 2), hepatitis B (phase 1) and genital warts/cervical dysplasia due to human papillomavirus | Recombinant subunit protein vaccine for hepatitis C and recombinant polyepitope vaccines for hepatitis B, C and human papillomavirus | Therapeutic vaccines for infectious disease as well as diagnostics, genetic testing and biomanufacture. Partnered with Bayer Diagnostics, Rhein Biotech, Roche Diagnostics, Abbott Laboratories, Epimmune PamlGene, Third Wave Technologies |
| MedImmune (Princeton, NJ, USA) | Influenza (FluMist; marketed), infectious mononucleosis (phase 2), pneumococcal disease (phase 1), respiratory disease due to respiratory syncytial virus (phase 1), | Cold-adapted live influenza virus vaccine, chimeric viral vaccine expressing recombinant proteins from viral pathogens, and recombinant vaccine against Streptococcus pneumoniae | Vaccines and antibody therapeutics in oncology, infectious diseases and immunology. Partnered with ViroNovative and Wyeth (co-promoter of FluMist) and GlaxoSmithKline |
| Nabi Biopharmaceuticals (Boca Raton, FL, USA) | Hospital-acquired staphylococci and enterococci infections (phase 1, 2/phase 3 completed) | Polysaccharide conjugate vaccines against staphylococci and enterococci | Vaccines and monoclonal antibodies against infectious disease. Partnered with Cambrex for manufacturing. Building own manufacturing facilities |
| Sinovac, Beijing, www.sinovac.com | Hepatitis A,B (marketed), flu, SARS (phase 1) | Inactivated whole virus or inactivated viral subunit vaccine | Research, development, commercialization and sales of human vaccines for infectious diseases |
| Solvay Pharmaceuticals (Brussels) | Influenza | Recombinant subunit protein vaccines for influenza produced in Madine Darby canine kidney cell culture | Vaccines, pharmaceuticals, chemicals and even plastics. Partnered in vaccines with Bena Biotech |
| United Biomedical (Hauppauge, NY, USA) | HIV and foot and mouth disease | Synthetic peptide-based vaccines | Peptide immunogens for use in vaccines and immunotherapies in human and animal health and contract manufacturing services |
| Vical (San Diego, CA, USA) | Anthrax (phase 1), infectious mononucleosis (phase 1), malaria (phase 1/2), Ebola (phase 1), West Nile (phase 1), SARS (phase 1), HIV (phase 1), hepatitis B, hepatitis C and H5N1 influenza | DNA vaccines delivered using cationic liposomes | DNA vaccines and gene therapies. Contract manufacturer of DNA plasmids. Partnered with Merck and National Institutes of Health for human health and Aqua Health and Merial for veterinary products |
Table 5  Selected private biotech companies with a business interest in prophylactic vaccine development

| Company (location)                  | Prophylactic vaccine focus (development phase, if any) | Technology                                                                 | Business strategy                                                                 |
|------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Antigenics (New York) http://www.antigenics.com/ | Genital herpes (phase 1/2)                              | Antigen from herpes simplex virus type 2 vaccine complexed with heat-shock protein | Developing immunotherapies for cancer, infectious diseases, autoimmune degenerative disorders. Partnered with GlaxoSmithKline, Wyeth, Aventis Pasteur, Progenics, Elan |
| Aridis Pharmaceuticals (Sunnyvale, CA, USA) | Shigella and rotavirus                                  | Dehydration technology and addition of stabilizers that enhance vaccine half-life | Developing new vaccine formulations, processing and delivery approaches. Partnered with the NIH |
| Avira (Glen Burnie, MD, USA) http://www.avrx.com/index.htm | Genital herpes (phase 1)                               | Herpes simplex virus type 2 vaccine attenuated by recombinant technology.   | Focused on vaccines and therapeutics for herpes simplex type 2. Partnered with the NIH |
| Avecia Biotechnology (Manchester, UK) http://www.avecia.com/biotech/default.htm | Plague and anthrax                                     | Oligonucleotide synthesis and biologic manufacture                          | Contract manufacturing services for DNA and protein vaccines                       |
| Bharat Biotech (Hyderabad, India) http://www.bharatbiotech.com/ | Hepatitis B (launched) and typhoid (launched) | Recombinant hepatitis B virus surface antigen vaccine and purified *Salmonella typhi* Vi capsular polysaccharide | Vaccines, biopharmaceuticals and biomanufacturing. Partnered with Mvelaphanda (S. African gold and diamond company) |
| BioVirus Research (Reno, NV, USA) | Genital herpes                                         | A computational platform for designing synthetic peptide vaccines           | Focused on vaccines and therapeutics for herpes simplex virus type 2. Partnered with Tekron (Ft. Lauderdale, FL) |
| Cerus (Concord, CA, USA) http://www.cerus.com | Anthrax                                                | Expression of antigens on killed but metabolically active strains of *Listeria monocytogenes* | Vaccines and blood safety products for infectious disease and cancer. Partnered with MedImmune, Baxter Healthcare, BioOne |
| Emergent Biosolutions (Gaithersburg, MD, USA) http://www.ebsi.com/home.asp | Anthrax, *Chlamydia trachomatis*, *Helicobacter pylori* and influenza | Aluminum hydroxide-adsorbed cell-free vaccine prepared from *Bacillus anthracis* strain V770-NP1-R | Vaccines and related products. BioPort manufacturing arm Antex Biologics, research arm acquired UK-based Microscience 2005. Expanded manufacturing capacity in 2004 with purchase of new facility in Frederick, Maryland |
| Epivax (Providence, RI, USA) http://epivax.com/ | *Helicobacter pylori* ulcers, tularemia and smallpox | A computational platform for identifying T-cell epitopes in peptide sequences | Research services for vaccine development |
| GenPhar (Mt. Pleasant, SC, USA) http://www.genphar.com/ | HIV (phase 1/2)                                         | Adenovirus vectors for antigen delivery                                      | Viral diagnostics, vaccines, cancer therapies. Partnered with NIH for testing HIV vaccine in monkeys and USAMIRD for Marburg |
| Hawaii Biotech (Aiea, HI, USA) http://www.hibiotech.com | Influenza, *West Nile virus*, and dengue fever         | Recombinant protein vaccines                                                 | Vaccines and small molecules. Partnered with Cobra for manufacture of dengue and West Nile vaccine |
| Novavax (Malvern, PA, USA) http://www.novavax.com | HIV, influenza, hepatitis E and SARS                   | Expression in insect cells of virus-like particle technology for expressing antigens | Vaccines, drug delivery and biologics. Partnered with National Institute of Allergy and Infectious Diseases (NIAID), Walter Reed Army Institute for Research and GlaxoSmithKline |
| Oxten Therapeutics (Oxford, UK) http://www.oxti.com | Malaria (phase 2), tuberculosis (phase 1) and HIV (phase 2) | Prime-boost vaccines based on recombinant modified vaccinia virus, Ankara-expressing antigens | Vaccines and other immunotherapies for infectious disease and cancer. Partnered with Wellcome Trust, Medical Research Council and Malaria Vaccine Initiative |
| PowderMed (Oxford, UK) http://www.powdermed.com/ | Influenza (phase 1), HIV (phase 1), genital warts and hepatitis B | DNA-based vaccine delivered by gene gun                                      | DNA vaccines. Partnered with GlaxoSmithKline (HIV)                                 |
| Protein Sciences (Meriden, CT, USA) http://www.proteinsciences.com/ | Influenza (phase 3) and SARS                           | Recombinant subunit protein vaccine produced in baculovirus expression system | Antigens and protein reagents, vaccines R&D and contract manufacturing services. Contract with NIAID to produce SARS S-protein subunit vaccine |
| Sciogen (San Francisco) http://www.sciogeninc.com/ | Influenza and SARS                                     | Live viral vaccines attenuated by recombinant technology                     | Vaccines and biopharmaceuticals                                                     |
Table 6  Selected vaccine supply contracts for project BioShield

| Company          | Product                                      | Pathogen                  | Award (millions) | Date         |
|------------------|----------------------------------------------|---------------------------|------------------|--------------|
| Acambis          | MVA3000                                       | Smallpox                  | $76.3            | 10/7/2004    |
|                  | Modified vaccinia Ankara (MVA) attenuate vaccine | Smallpox               | $10              | 02/25/2003   |
|                  | ACAM2000 clonal cell culture vaccine          | Smallpox                  | $428             | 11/28/2001 a |
| Bavarian Nordic  | Imvamune MVA                                  | Smallpox                  | $100             | 10/07/2004   |
|                  |                                              | Smallpox                  | $23 b            | 09/25/2003   |
| BioPort          | Anthrax vaccine, 5-million doses              | Bacillus anthracis        | $122.7           | 05/06/2005   |
| DynaPort         | Vaccine development, pilot production         | Francisella tulareamia    | $35.1            | 10/05/2005   |
|                  | Vaccine development                           | Francisella tulareamia, Clostridium botulinum, Venezuelan equine encephalitis virus | $19.7 | 12/07/2004   |
|                  | Hepatavalent vaccine development              | Clostridium botulinum     | $11              | 09/04/2003   |
|                  | Live attenuated vaccine                       | Francisella tulareamia    | $4.6             | 10/07/2004   |
| VaxGen           | rPA102, 75 million doses                      | Anthrax                   | $877.5           | 11/04/2004   |
|                  | rPA102, clinical trials                       | Anthrax                   | $80.3            | 09/02/2003   |
|                  | rPA102                                        | Anthrax                   | $11 b (approximate) | 10/02/2002   |

Source: US Department of Health & Human Services. aOriginal order for 209 million doses cut to 182.5 million doses. bGrants shared by two companies, individual grant not disclosed.

Table 7  Biotech companies with Bioshield vaccine projects

| Company (location) | Project (clinical development)                                      |
|--------------------|---------------------------------------------------------------------|
| Aridis Pharmaceuticals | Live, oral heat stable *Salmonella typhi* vaccine                   |
| Avant Immunotherapies | Bacterial, viral, biodefense vaccines                               |
| Avecia Biotechnology | Recombinant plague and anthrax protein vaccines                     |
| Cerus              | Anthrax                                                             |
| Curalab (Stoughton, MA, USA) | Universal influenza vaccine cell line                           |
| Epivax             | Tulareamia epitope vaccine and smallpox vaccine from Immunome       |
| Hawaii Biotech      | Recombinant subunit influenza vaccine                               |
| Intercell          | Japanese encephalitis virus (phase 3)                              |
| Iomai              | Transcutaneous vaccination influenza (phase 2), traveler’s diarrhea (phase 2), anthrax (phase 1) and influenza (phase 1) |
| L2 Diagnostics (New Haven, CT, USA) | Recombinant West Nile subunit vaccine                           |
| Medarex (Princeton, NJ, USA) | Improved targeted anthrax vaccine                                |
| Novavax            | Virus-like particle vaccines for influenza, hepatitis E and SARS    |
| Scioigen           | Recombinant influenza vaccine                                       |
| Technovan          | Virus-like particles as vaccines                                    |
| Vical              | Anthrax, infectious mononucleosis, malaria, Ebola, West Nile, SARS, HIV, hepatitis B, hepatitis C, H5N1 influenza |

Over the coming years, it also aims to launch Streptorix, (a ten-valent *S. pneumoniae* conjugated vaccine) a competitor to Prevnar that will protect against ten *S. pneumoniae* serotypes, and Rotarix, an oral, live attenuated vaccine, which prevents rotavirus infection, among other products.

**New mind-set**

There is still a tension, however, between what the market—or regulators—will accept and what modern molecular biology can deliver. The pace of innovation in the vaccine industry has been slow, partly because of the inherent difficulty of developing effective new vaccines and partly because of the inertia engendered by an historically stagnant market. Putative blockbusters notwithstanding, much of the recent product development activity conducted by the main vaccine manufacturers has consisted of adding incremental improvements and enhancements to their existing portfolios. Many new product approvals consist of combinations of vaccines that are already on the market. From a commercial perspective combination vaccines have an easier path because a precedent has been already set for their ’need’ in the marketplace. From a regulatory perspective the combo vaccine still has to prove the same levels of afforded immunogenicity as the single components. Genuinely novel products that address new antigens or pathogens against which there is no current protection are rare.

“I think the problem we all face is the people in the vaccine industry have started from a very low technological base,” says Clive Dix, CEO of Oxford, UK-based PowderMed. A “cheap and cheerful” mentality still exists, he says, which requires vaccines to be low-tech and low-cost. Nevertheless, novel ideas and novel approaches are beginning to filter through. But there is also a considerable backlog of work to be done on simply hauling ineffective or limited vaccines, or those produced via crude production methods, into the molecular biology era.

1. Scherer F.M.  American Anti-Trust Institute Working Paper 04-03 29 (American Anti-Trust Institute, Washington, DC, October 2004). http://www.anti-trustinstitute.org/recent2/351.pdf
2. Datamonitor. Commercial Perspectives: Vaccines (Datamonitor, London, January 2004).
3. Ulmer J.B. *et al*., Heterologous protection against influenza by infection of DNA encoding a viral protein. *Science* **259**, 1691–1692 (1993).